ASP Isotopes Inc. Files 8-K with Corporate Details
Ticker: ASPI · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1921865
Sentiment: neutral
Topics: corporate-info, 8-k
TL;DR
ASP Isotopes Inc. filed an 8-K on 12/18/25 with basic corporate info. Nothing major.
AI Summary
ASP Isotopes Inc. filed an 8-K on December 18, 2025, reporting information under Regulation FD. The filing details the company's principal executive offices located at 601 Pennsylvania Avenue NW, South Building, Suite 900, Washington, DC 20004, and its principal business phone number is (202) 756-2245. The company is incorporated in Delaware and has an IRS Employer Identification No. of 87-2618235.
Why It Matters
This filing provides essential corporate information and contact details for ASP Isotopes Inc., which is important for investors and stakeholders to understand the company's basic structure and location.
Risk Assessment
Risk Level: low — The filing is a routine 8-K providing corporate details and does not disclose any new material events or financial information that would indicate increased risk.
Key Players & Entities
- ASP Isotopes Inc. (company) — Registrant
- December 18, 2025 (date) — Date of earliest event reported
- 601 Pennsylvania Avenue NW, South Building, Suite 900, Washington, DC 20004 (address) — Principal executive offices
- (202) 756-2245 (phone_number) — Registrant's telephone number
- Delaware (jurisdiction) — State of incorporation
- 87-2618235 (ein) — IRS Employer Identification No.
- 001-41555 (commission_file_number) — SEC File Number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 18, 2025.
What is the principal business address of ASP Isotopes Inc.?
The principal executive offices are located at 601 Pennsylvania Avenue NW, South Building, Suite 900, Washington, DC 20004.
What is the telephone number for ASP Isotopes Inc.?
The registrant's telephone number, including area code, is (202) 756-2245.
In which state is ASP Isotopes Inc. incorporated?
ASP Isotopes Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number for ASP Isotopes Inc.?
The IRS Employer Identification Number for ASP Isotopes Inc. is 87-2618235.
Filing Stats: 1,523 words · 6 min read · ~5 pages · Grade level 18.9 · Accepted 2025-12-18 07:34:11
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 ASPI The Nasdaq Stock Market LLC
Filing Documents
- aspi_8k.htm (8-K) — 45KB
- 0001477932-25-009035.txt ( ) — 167KB
- aspi-20251218.xsd (EX-101.SCH) — 5KB
- aspi-20251218_lab.xml (EX-101.LAB) — 15KB
- aspi-20251218_cal.xml (EX-101.CAL) — 1KB
- aspi-20251218_pre.xml (EX-101.PRE) — 10KB
- aspi-20251218_def.xml (EX-101.DEF) — 2KB
- aspi_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 18, 2025, ASP Isotopes Inc. (the "Company" or "ASP Isotopes") confirmed that the South African Takeover Regulation Panel has issued a compliance certificate in connection with the scheme of arrangement under South African law pursuant to which ASP Isotopes will offer to acquire all of the issued ordinary shares of JSE-listed Renergen Limited ("Renergen") and Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date (the "Scheme") and that, as a result, the Scheme can now proceed to implementation. The remaining salient dates and times for the implementation of the Scheme are set out below: Compliance certificate received from the Takeover Panel on Thursday, 18 December 2025 Scheme Finalisation Date Thursday, 18 December 2025 Scheme Finalisation Date announcement released on SENS by 09:00 SAST and on the ASX by 17:00 AEST on Thursday, 18 December 2025 Application for delisting of Renergen Shares lodged with the JSE and the ASX Friday, 19 December 2025 Public Holiday in South African, Australia and USA Thursday, 25 December 2025 Public Holiday in South African and Australia Friday, 26 December 2025 Last day for Renergen Shareholders to request to reposition securities between the South African Register and the Australian Register to ensure that it is completed before the Scheme JSE LDT Monday, 29 December 2025 Scheme JSE LDT in Renergen Shares on the JSE Monday, 29 December 2025 Trading in Renergen Shares on the JSE to be suspended from commencement of trade on Tuesday, 30 December 2025 Scheme ASX LDT in CDIs on the ASX Tuesday, 30 December 2025 Scheme Consideration Shares listed on the JSE at commencement of trade (09:00 SAST) on ( see note 1 below ) Tuesday, 30 December 2025 Trading by Scheme Participants recorded in the South African Register in the entitlements to the Scheme Consideration Shares listed on the JSE on 30 December 202
Forward Looking Statements
Forward Looking Statements This Form 8-K contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like "may," "will," "likely," "should," "expect," "anticipate," "future," "plan," "believe," "intend," "goal," "seek," "estimate," "project," "continue," and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: (i) the implementation of the Scheme in the anticipated timeframe or at all; (ii) the ability to realize the anticipated benefits of the proposed acquisition of Renergen; (iii) the ability to successfully integrate the businesses; (iv) disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; (v) the negative effects of this announcement or the consummation of the proposed acquisition of Renergen on the market price of Renergen's or ASPI's securities; (vi) significant transaction costs and unknown liabilities; (vii) litigation or regulatory actions related to the proposed acquisition of Renergen; and (viii) such other factors as are set forth in the periodic reports filed by ASPI with the U.S. Securities and Exchange Commission (the "SEC"), including but not limited to those described under the heading "Risk Factors" in its annual reports on Form 10-K, quarterly reports on Form 10-Q and any other filings made with the SEC from time to time, which are available via the SEC's website at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking st
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASP ISOTOPES INC. Date: December 18, 2025 By: /s/ Donald G. Ainscow Name: Donald G. Ainscow Title: Executive Vice President, General Counsel and Secretary 4